vs
阿斯利康（AZN）与摩根士丹利（MS）财务数据对比。点击上方公司名可切换其他公司
摩根士丹利的季度营收约是阿斯利康的1.2倍（$17.9B vs $14.5B），摩根士丹利净利率更高（24.6% vs 16.9%，领先7.6%）
阿斯利康是一家瑞典与英国合资的跨国制药及生物技术企业，总部位于英国剑桥的剑桥生物医学园区。公司产品管线覆盖肿瘤、心血管、消化、感染、神经科学、呼吸、炎症等重大疾病领域。
摩根士丹利是总部位于美国纽约曼哈顿中城百老汇1585号的跨国投资银行及金融服务提供商，在全球42个国家设有办事处，员工超8万名，服务客户涵盖企业、政府、机构及个人。2023年该公司位列美国财富500强第61位，同年位居福布斯全球2000强第30位。
AZN vs MS — 直观对比
营收规模更大
MS
是对方的1.2倍
$14.5B
净利率更高
MS
高出7.6%
16.9%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $14.5B | $17.9B |
| 净利润 | $2.4B | $4.4B |
| 毛利率 | 82.9% | — |
| 营业利润率 | 24.3% | 32.2% |
| 净利率 | 16.9% | 24.6% |
| 营收同比 | 11.7% | — |
| 净利润同比 | 27.0% | — |
| 每股收益（稀释后） | $1.57 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AZNMS
| Q4 25 | — | $17.9B | ||
| Q3 25 | — | $18.2B | ||
| Q2 25 | $14.5B | $16.8B | ||
| Q1 25 | — | $17.7B | ||
| Q3 24 | — | $15.4B | ||
| Q2 24 | $12.9B | $15.0B | ||
| Q1 24 | — | $15.1B | ||
| Q2 23 | $11.4B | — |
净利润AZNMS
| Q4 25 | — | $4.4B | ||
| Q3 25 | — | $4.6B | ||
| Q2 25 | $2.4B | $3.5B | ||
| Q1 25 | — | $4.3B | ||
| Q3 24 | — | $3.2B | ||
| Q2 24 | $1.9B | $3.1B | ||
| Q1 24 | — | $3.4B | ||
| Q2 23 | $1.8B | — |
毛利率AZNMS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 82.9% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 83.1% | — | ||
| Q1 24 | — | — | ||
| Q2 23 | 82.8% | — |
营业利润率AZNMS
| Q4 25 | — | 32.2% | ||
| Q3 25 | — | 33.1% | ||
| Q2 25 | 24.3% | 27.5% | ||
| Q1 25 | — | 31.3% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | 21.2% | 27.1% | ||
| Q1 24 | — | 29.0% | ||
| Q2 23 | 21.5% | — |
净利率AZNMS
| Q4 25 | — | 24.6% | ||
| Q3 25 | — | 25.3% | ||
| Q2 25 | 16.9% | 21.1% | ||
| Q1 25 | — | 24.3% | ||
| Q3 24 | — | 20.7% | ||
| Q2 24 | 14.9% | 20.5% | ||
| Q1 24 | — | 22.5% | ||
| Q2 23 | 15.9% | — |
每股收益（稀释后）AZNMS
| Q4 25 | — | $2.68 | ||
| Q3 25 | — | $2.80 | ||
| Q2 25 | $1.57 | $2.13 | ||
| Q1 25 | — | $2.60 | ||
| Q3 24 | — | $1.88 | ||
| Q2 24 | $1.24 | $1.82 | ||
| Q1 24 | — | $2.02 | ||
| Q2 23 | $1.17 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.1B | $111.7B |
| 总债务越低越好 | — | $341.7B |
| 股东权益账面价值 | $44.8B | $111.6B |
| 总资产 | $112.4B | $1420.3B |
| 负债/权益比越低杠杆越低 | — | 3.06× |
8季度趋势，按日历期对齐
现金及短期投资AZNMS
| Q4 25 | — | $111.7B | ||
| Q3 25 | — | $103.7B | ||
| Q2 25 | $7.1B | $109.1B | ||
| Q1 25 | — | $90.7B | ||
| Q3 24 | — | $91.1B | ||
| Q2 24 | $6.9B | $90.2B | ||
| Q1 24 | — | $102.3B | ||
| Q2 23 | $5.7B | — |
总债务AZNMS
| Q4 25 | — | $341.7B | ||
| Q3 25 | — | $324.1B | ||
| Q2 25 | — | $320.1B | ||
| Q1 25 | — | $297.0B | ||
| Q3 24 | — | $291.2B | ||
| Q2 24 | — | $269.9B | ||
| Q1 24 | — | $266.1B | ||
| Q2 23 | — | — |
股东权益AZNMS
| Q4 25 | — | $111.6B | ||
| Q3 25 | — | $110.0B | ||
| Q2 25 | $44.8B | $108.2B | ||
| Q1 25 | — | $106.8B | ||
| Q3 24 | — | $103.6B | ||
| Q2 24 | $39.6B | $100.7B | ||
| Q1 24 | — | $99.2B | ||
| Q2 23 | $37.4B | — |
总资产AZNMS
| Q4 25 | — | $1420.3B | ||
| Q3 25 | — | $1364.8B | ||
| Q2 25 | $112.4B | $1353.9B | ||
| Q1 25 | — | $1300.3B | ||
| Q3 24 | — | $1258.0B | ||
| Q2 24 | $104.3B | $1212.4B | ||
| Q1 24 | — | $1228.5B | ||
| Q2 23 | $96.5B | — |
负债/权益比AZNMS
| Q4 25 | — | 3.06× | ||
| Q3 25 | — | 2.95× | ||
| Q2 25 | — | 2.96× | ||
| Q1 25 | — | 2.78× | ||
| Q3 24 | — | 2.81× | ||
| Q2 24 | — | 2.68× | ||
| Q1 24 | — | 2.68× | ||
| Q2 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-2.4B |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -0.55× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AZNMS
| Q4 25 | — | $-2.4B | ||
| Q3 25 | — | $-3.3B | ||
| Q2 25 | — | $11.8B | ||
| Q1 25 | — | $-24.0B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $4.4B | ||
| Q2 23 | — | — |
现金转化率AZNMS
| Q4 25 | — | -0.55× | ||
| Q3 25 | — | -0.72× | ||
| Q2 25 | — | 3.34× | ||
| Q1 25 | — | -5.56× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.28× | ||
| Q2 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
